Cargando…

A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study

Purpose: Embolotherapy using microshperes is currently performed with soluble contrast to aid in visualization. However, administered payload visibility dimishes soon after delivery due to soluble contrast washout, leaving the radiolucent bead's location unknown. The objective of our study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran, Rafael, Sharma, Karun, Dreher, Matthew R., Ashrafi, Koorosh, Mirpour, Sahar, Lin, MingDe, Schernthaner, Ruediger E., Schlachter, Todd R., Tacher, Vania, Lewis, Andrew L., Willis, Sean, den Hartog, Mark, Radaelli, Alessandro, Negussie, Ayele H., Wood, Bradford J., Geschwind, Jean-François H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679352/
https://www.ncbi.nlm.nih.gov/pubmed/26722371
http://dx.doi.org/10.7150/thno.13137
_version_ 1782405566670307328
author Duran, Rafael
Sharma, Karun
Dreher, Matthew R.
Ashrafi, Koorosh
Mirpour, Sahar
Lin, MingDe
Schernthaner, Ruediger E.
Schlachter, Todd R.
Tacher, Vania
Lewis, Andrew L.
Willis, Sean
den Hartog, Mark
Radaelli, Alessandro
Negussie, Ayele H.
Wood, Bradford J.
Geschwind, Jean-François H.
author_facet Duran, Rafael
Sharma, Karun
Dreher, Matthew R.
Ashrafi, Koorosh
Mirpour, Sahar
Lin, MingDe
Schernthaner, Ruediger E.
Schlachter, Todd R.
Tacher, Vania
Lewis, Andrew L.
Willis, Sean
den Hartog, Mark
Radaelli, Alessandro
Negussie, Ayele H.
Wood, Bradford J.
Geschwind, Jean-François H.
author_sort Duran, Rafael
collection PubMed
description Purpose: Embolotherapy using microshperes is currently performed with soluble contrast to aid in visualization. However, administered payload visibility dimishes soon after delivery due to soluble contrast washout, leaving the radiolucent bead's location unknown. The objective of our study was to characterize inherently radiopaque beads (RO Beads) in terms of physicomechanical properties, deliverability and imaging visibility in a rabbit VX2 liver tumor model. Materials and Methods: RO Beads, which are based on LC Bead® platform, were compared to LC Bead. Bead size (light microscopy), equilibrium water content (EWC), density, X-ray attenuation and iodine distribution (micro-CT), suspension (settling times), deliverability and in vitro penetration were investigated. Fifteen rabbits were embolized with either LC Bead or RO Beads + soluble contrast (iodixanol-320), or RO Beads+dextrose. Appearance was evaluated with fluoroscopy, X-ray single shot, cone-beam CT (CBCT). Results: Both bead types had a similar size distribution. RO Beads had lower EWC (60-72%) and higher density (1.21-1.36 g/cc) with a homogeneous iodine distribution within the bead's interior. RO Beads suspension time was shorter than LC Bead, with durable suspension (>5 min) in 100% iodixanol. RO Beads ≤300 µm were deliverable through a 2.3-Fr microcatheter. Both bead types showed similar penetration. Soluble contrast could identify target and non-target embolization on fluoroscopy during administration. However, the imaging appearance vanished quickly for LC Bead as contrast washed-out. RO Beads+contrast significantly increased visibility on X-ray single shot compared to LC Bead+contrast in target and non-target arteries (P=0.0043). Similarly, RO beads demonstrated better visibility on CBCT in target arteries (P=0.0238) with a trend in non-target arteries (P=0.0519). RO Beads+dextrose were not sufficiently visible to monitor embolization using fluoroscopy. Conclusion: RO Beads provide better conspicuity to determine target and non-target embolization compared to LC Bead which may improve intra-procedural monitoring and post-procedural evaluation of transarterial embolization.
format Online
Article
Text
id pubmed-4679352
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-46793522016-01-01 A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study Duran, Rafael Sharma, Karun Dreher, Matthew R. Ashrafi, Koorosh Mirpour, Sahar Lin, MingDe Schernthaner, Ruediger E. Schlachter, Todd R. Tacher, Vania Lewis, Andrew L. Willis, Sean den Hartog, Mark Radaelli, Alessandro Negussie, Ayele H. Wood, Bradford J. Geschwind, Jean-François H. Theranostics Research Paper Purpose: Embolotherapy using microshperes is currently performed with soluble contrast to aid in visualization. However, administered payload visibility dimishes soon after delivery due to soluble contrast washout, leaving the radiolucent bead's location unknown. The objective of our study was to characterize inherently radiopaque beads (RO Beads) in terms of physicomechanical properties, deliverability and imaging visibility in a rabbit VX2 liver tumor model. Materials and Methods: RO Beads, which are based on LC Bead® platform, were compared to LC Bead. Bead size (light microscopy), equilibrium water content (EWC), density, X-ray attenuation and iodine distribution (micro-CT), suspension (settling times), deliverability and in vitro penetration were investigated. Fifteen rabbits were embolized with either LC Bead or RO Beads + soluble contrast (iodixanol-320), or RO Beads+dextrose. Appearance was evaluated with fluoroscopy, X-ray single shot, cone-beam CT (CBCT). Results: Both bead types had a similar size distribution. RO Beads had lower EWC (60-72%) and higher density (1.21-1.36 g/cc) with a homogeneous iodine distribution within the bead's interior. RO Beads suspension time was shorter than LC Bead, with durable suspension (>5 min) in 100% iodixanol. RO Beads ≤300 µm were deliverable through a 2.3-Fr microcatheter. Both bead types showed similar penetration. Soluble contrast could identify target and non-target embolization on fluoroscopy during administration. However, the imaging appearance vanished quickly for LC Bead as contrast washed-out. RO Beads+contrast significantly increased visibility on X-ray single shot compared to LC Bead+contrast in target and non-target arteries (P=0.0043). Similarly, RO beads demonstrated better visibility on CBCT in target arteries (P=0.0238) with a trend in non-target arteries (P=0.0519). RO Beads+dextrose were not sufficiently visible to monitor embolization using fluoroscopy. Conclusion: RO Beads provide better conspicuity to determine target and non-target embolization compared to LC Bead which may improve intra-procedural monitoring and post-procedural evaluation of transarterial embolization. Ivyspring International Publisher 2016-01-01 /pmc/articles/PMC4679352/ /pubmed/26722371 http://dx.doi.org/10.7150/thno.13137 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Duran, Rafael
Sharma, Karun
Dreher, Matthew R.
Ashrafi, Koorosh
Mirpour, Sahar
Lin, MingDe
Schernthaner, Ruediger E.
Schlachter, Todd R.
Tacher, Vania
Lewis, Andrew L.
Willis, Sean
den Hartog, Mark
Radaelli, Alessandro
Negussie, Ayele H.
Wood, Bradford J.
Geschwind, Jean-François H.
A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
title A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
title_full A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
title_fullStr A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
title_full_unstemmed A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
title_short A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
title_sort novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679352/
https://www.ncbi.nlm.nih.gov/pubmed/26722371
http://dx.doi.org/10.7150/thno.13137
work_keys_str_mv AT duranrafael anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT sharmakarun anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT drehermatthewr anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT ashrafikoorosh anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT mirpoursahar anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT linmingde anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT schernthanerruedigere anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT schlachtertoddr anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT tachervania anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT lewisandrewl anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT willissean anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT denhartogmark anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT radaellialessandro anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT negussieayeleh anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT woodbradfordj anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT geschwindjeanfrancoish anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT duranrafael novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT sharmakarun novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT drehermatthewr novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT ashrafikoorosh novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT mirpoursahar novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT linmingde novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT schernthanerruedigere novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT schlachtertoddr novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT tachervania novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT lewisandrewl novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT willissean novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT denhartogmark novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT radaellialessandro novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT negussieayeleh novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT woodbradfordj novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy
AT geschwindjeanfrancoish novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy